Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases

Sex: All

Ages: 30 Years – 74 Years

Healthy volunteers: No

Enrollment: 46

Sponsor: First Affiliated Hospital of Fujian Medical University

Location: Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University Fuzhou Fujian

Summary

68-Ga-DOTATATE is a radiotracer targeting somatostatin receptors (SSTR). In this study, we investigated the diagnostic efficacy of delayed \^68\^Ga-DOTATATE PET/MR in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and liver metastases, and performed a head-to-head comparison with conventional 68-Ga-DOTATATE PET/CT.

Eligibility Criteria

Inclusion Criteria: (a)Histologically confirmed well-differentiated GEP-NETs via biopsy or surgical resection in adults aged 18-80 years,(b) confirmed or suspected liver metastases, as determined by previous imaging studies or PET/CT scans,(c) availability of comprehensive surgical reports, pathological findings, comparative data, and clinical follow-up outcomes for analysis,(d) absence of PET/MR contraindications , with voluntary participation and signed informed consent forms adhering to ethical and research guidelines Exclusion Criteria: (a) unavailability of surgical, pathological or long-term follow-up data; (b) non-compliance with age eligibility criteria or presence of comorbidities compromising protocol adherence

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07898904). StuddyBuddy aggregates publicly available trial information.